KalVista Pharmaceuticals, Inc. (KALV) News
Filter KALV News Items
KALV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KALV News Highlights
- KALV's 30 day story count now stands at 4.
- Over the past 15 days, the trend for KALV's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest KALV News From Around the Web
Below are the latest news stories about KALVISTA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate KALV as an investment opportunity.
KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in PharmacologyCAMBRIDGE, Mass. & SALISBURY, England, December 20, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that data from the first report of an oral, potent, and selective FXIIa inhibitor has been published in the peer-reviewed scientific journal, Frontiers in Pharmacology. |
KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024. |
KalVista Pharmaceuticals Inc (KALV) Reports Second Fiscal Quarter ResultsAdvances in Clinical Trials and Increased R&D Expenses Mark the Quarter |
KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateCAMBRIDGE, Mass. & SALISBURY, England, December 07, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023. |
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass. & SALISBURY, England, December 05, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted four newly-hired employees inducement options to purchase an aggregate of 43,000 shares of KalVista common stock on December 1, 2023 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
Insider Sell Alert: CEO Thomas Crockett Offloads Shares of KalVista Pharmaceuticals IncIn the realm of stock market movements, insider trading activity is often a significant indicator that investors keep a close eye on. |
Insider Sell Alert: KalVista Pharmaceuticals Inc's Benjamin Palleiko Sells 13,008 SharesIn a notable insider transaction, Benjamin Palleiko, the President, CFO, CBO & Sec'y of KalVista Pharmaceuticals Inc (NASDAQ:KALV), sold 13,008 shares of the company on November 20, 2023. |
3 Micro-Cap Stocks That Could Be MoonshotsIf you are hungry for high-risk returns, then these micro-cap stocks to buy could be your winning ticket to future yields. |
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & ImmunologyCAMBRIDGE, Mass. & SALISBURY, England, November 14, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand |
KalVista Pharmaceuticals Announces Phase 3 KONFIDENT Trial Milestone AchievedCAMBRIDGE, Mass. & SALISBURY, England, November 13, 2023--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided clinical trial and regulatory updates for its lead program sebetralstat, in development as a potential oral on-demand therapy for hereditary angioedema (HAE). |